GENFIT Share Price Other OTC
Stocks
GNFTF
FR0004163111
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 645M 737M 596M 548M 1.03B 71.06B 1.06B 7.12B 2.8B 34.78B 2.77B 2.71B 120B | P/E 2026 * |
67.8x | P/E 2027 * | 85.7x |
|---|---|---|---|---|---|
| Enterprise Value | 594M 679M 549M 505M 951M 65.43B 974M 6.56B 2.58B 32.02B 2.55B 2.49B 110B | EV / Sales 2026 * |
5.93x | EV / Sales 2027 * | 4.67x |
| Free-Float |
86.88% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -3.28% |
| Manager | Title | Age | Since |
|---|---|---|---|
Pascal Prigent
CEO | Chief Executive Officer | 58 | 15/09/2019 |
Thomas Baetz
DFI | Director of Finance/CFO | 52 | 21/04/2021 |
Pejvack Motlagh
CTO | Chief Tech/Sci/R&D Officer | - | 26/11/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | 15/06/2017 | |
| Director/Board Member | 54 | 14/09/1999 | |
| Director/Board Member | 58 | 15/06/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.28% | -.--% | - | - | 738M | |
| -1.29% | -3.11% | -0.35% | +3.09% | 49.18B | |
| +3.90% | -0.39% | +386.06% | +593.85% | 39.58B | |
| -1.70% | +4.46% | +5.93% | +60.25% | 34.69B | |
| -2.01% | -0.76% | +28.41% | -8.01% | 34.42B | |
| +0.06% | +0.34% | +2.38% | +34.38% | 27.11B | |
| +0.46% | -3.49% | - | - | 16.21B | |
| -0.04% | -0.09% | +72.42% | +115.55% | 15.36B | |
| +1.12% | +1.91% | +14.54% | +19.16% | 14.05B | |
| 0.00% | +1.36% | +18.43% | -30.79% | 13.02B | |
| Average | -0.28% | +0.03% | +65.98% | +98.43% | 27.07B | |
| Weighted average by Cap. | -0.06% | -0.18% | +79.44% | +123.32% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 100M 115M 92.5M 85.15M 160M 11.03B 164M 1.11B 435M 5.4B 430M 420M 18.59B | 124M 142M 115M 105M 199M 13.66B 203M 1.37B 538M 6.68B 532M 521M 23.02B |
| Net income | 22.88M 26.14M 21.12M 19.44M 36.63M 2.52B 37.51M 252M 99.28M 1.23B 98.17M 96.01M 4.25B | 6.8M 7.77M 6.28M 5.78M 10.89M 749M 11.15M 75.04M 29.51M 366M 29.18M 28.54M 1.26B |
| Net Debt | -51.12M -58.42M -47.19M -43.44M -81.84M -5.63B -83.81M -564M -222M -2.75B -219M -215M -9.49B | -66.17M -75.62M -61.09M -56.23M -106M -7.29B -108M -730M -287M -3.57B -284M -278M -12.28B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
